NO324627B1 - Fremgangsmate ved opprenskning av antitrombin-III - Google Patents

Fremgangsmate ved opprenskning av antitrombin-III Download PDF

Info

Publication number: NO324627B1
Authority: NO; Norway
Prior art keywords: iii; polysorbate; antithrombin; citrate; saccharide
Prior art date: 1999-06-23

Application number

NO20016174A

Other languages

English (en)

Norwegian (no)

Other versions

NO20016174D0 (no

NO20016174L (no

Inventor

Stefan Winge

Original Assignee

Octapharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-23

Filing date

2001-12-18

Publication date

2007-11-26

2001-12-18 Application filed by Octapharma Ag filed Critical Octapharma Ag

2001-12-18 Publication of NO20016174D0 publication Critical patent/NO20016174D0/no

2002-02-21 Publication of NO20016174L publication Critical patent/NO20016174L/no

2007-11-26 Publication of NO324627B1 publication Critical patent/NO324627B1/no

Links

102000004411 Antithrombin III Human genes 0.000 title claims abstract description 104
108090000935 Antithrombin III Proteins 0.000 title claims abstract description 104
229960005348 antithrombin iii Drugs 0.000 title claims abstract description 103
238000000034 method Methods 0.000 title claims abstract description 33
150000001720 carbohydrates Chemical class 0.000 claims abstract description 29
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims abstract description 26
239000012535 impurity Substances 0.000 claims abstract description 23
238000000746 purification Methods 0.000 claims abstract description 22
229920000053 polysorbate 80 Polymers 0.000 claims description 31
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 30
-1 fatty acid ester Chemical class 0.000 claims description 24
229930006000 Sucrose Natural products 0.000 claims description 22
239000005720 sucrose Substances 0.000 claims description 22
239000001509 sodium citrate Substances 0.000 claims description 18
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 16
229940068968 polysorbate 80 Drugs 0.000 claims description 16
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 16
239000003381 stabilizer Substances 0.000 claims description 16
229920000136 polysorbate Polymers 0.000 claims description 14
238000009928 pasteurization Methods 0.000 claims description 12
229920001214 Polysorbate 60 Polymers 0.000 claims description 10
235000014113 dietary fatty acids Nutrition 0.000 claims description 10
239000000194 fatty acid Substances 0.000 claims description 10
229930195729 fatty acid Natural products 0.000 claims description 10
238000004108 freeze drying Methods 0.000 claims description 8
229950008882 polysorbate Drugs 0.000 claims description 8
229920001213 Polysorbate 20 Polymers 0.000 claims description 4
229920001219 Polysorbate 40 Polymers 0.000 claims description 3
150000002772 monosaccharides Chemical class 0.000 claims description 3
239000002736 nonionic surfactant Substances 0.000 claims description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
229920002642 Polysorbate 65 Polymers 0.000 claims description 2
229920002651 Polysorbate 85 Polymers 0.000 claims description 2
150000002016 disaccharides Chemical class 0.000 claims description 2
239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 2
235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 2
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 claims description 2
235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 claims description 2
229940068977 polysorbate 20 Drugs 0.000 claims description 2
229940101027 polysorbate 40 Drugs 0.000 claims description 2
229940113124 polysorbate 60 Drugs 0.000 claims description 2
229940099511 polysorbate 65 Drugs 0.000 claims description 2
229940113171 polysorbate 85 Drugs 0.000 claims description 2
125000000185 sucrose group Chemical group 0.000 claims 1
238000001556 precipitation Methods 0.000 abstract description 26
239000012905 visible particle Substances 0.000 abstract description 5
239000008194 pharmaceutical composition Substances 0.000 abstract description 3
239000000203 mixture Substances 0.000 description 28
239000000243 solution Substances 0.000 description 27
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 21
239000002245 particle Substances 0.000 description 20
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
238000009472 formulation Methods 0.000 description 15
241000700605 Viruses Species 0.000 description 14
239000000047 product Substances 0.000 description 14
239000004019 antithrombin Substances 0.000 description 13
230000000694 effects Effects 0.000 description 13
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
238000002360 preparation method Methods 0.000 description 11
235000018102 proteins Nutrition 0.000 description 9
102000004169 proteins and genes Human genes 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 8
150000003839 salts Chemical class 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 7
239000012141 concentrate Substances 0.000 description 7
230000001376 precipitating effect Effects 0.000 description 7
238000000108 ultra-filtration Methods 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
229960002897 heparin Drugs 0.000 description 6
229920000669 heparin Polymers 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
239000002202 Polyethylene glycol Substances 0.000 description 5
229920002684 Sepharose Polymers 0.000 description 5
238000001914 filtration Methods 0.000 description 5
230000002779 inactivation Effects 0.000 description 5
239000007788 liquid Substances 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
238000011084 recovery Methods 0.000 description 5
108010088751 Albumins Proteins 0.000 description 4
102000009027 Albumins Human genes 0.000 description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
241000125945 Protoparvovirus Species 0.000 description 4
238000001042 affinity chromatography Methods 0.000 description 4
229940050528 albumin Drugs 0.000 description 4
239000011734 sodium Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000011282 treatment Methods 0.000 description 4
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 3
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
239000004472 Lysine Substances 0.000 description 3
208000001435 Thromboembolism Diseases 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000003599 detergent Substances 0.000 description 3
238000001035 drying Methods 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
229960003646 lysine Drugs 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
239000000463 material Substances 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
239000001508 potassium citrate Substances 0.000 description 3
229960002635 potassium citrate Drugs 0.000 description 3
QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 3
235000011082 potassium citrates Nutrition 0.000 description 3
STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 3
239000008215 water for injection Substances 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
238000011049 filling Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
229950006191 gluconic acid Drugs 0.000 description 2
239000008103 glucose Substances 0.000 description 2
229960001031 glucose Drugs 0.000 description 2
229960002449 glycine Drugs 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
229960001855 mannitol Drugs 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
239000002904 solvent Substances 0.000 description 2
229960002920 sorbitol Drugs 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
201000005657 Antithrombin III deficiency Diseases 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000013271 Hemopexin Human genes 0.000 description 1
108010026027 Hemopexin Proteins 0.000 description 1
102100027619 Histidine-rich glycoprotein Human genes 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
102000029797 Prion Human genes 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
NCHJGQKLPRTMAO-XWVZOOPGSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NCHJGQKLPRTMAO-XWVZOOPGSA-N 0.000 description 1
IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229960003767 alanine Drugs 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
238000010908 decantation Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
239000000539 dimer Substances 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000033666 hereditary antithrombin deficiency Diseases 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229960002885 histidine Drugs 0.000 description 1
108010044853 histidine-rich proteins Proteins 0.000 description 1
238000000760 immunoelectrophoresis Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229960005336 magnesium citrate Drugs 0.000 description 1
239000004337 magnesium citrate Substances 0.000 description 1
235000002538 magnesium citrate Nutrition 0.000 description 1
229960002160 maltose Drugs 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000011045 prefiltration Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000020964 regulation of blood coagulation Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229960005480 sodium caprylate Drugs 0.000 description 1
BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
229940074404 sodium succinate Drugs 0.000 description 1
ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000001587 sorbitan monostearate Substances 0.000 description 1
235000011076 sorbitan monostearate Nutrition 0.000 description 1
229940035048 sorbitan monostearate Drugs 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
239000001589 sorbitan tristearate Substances 0.000 description 1
235000011078 sorbitan tristearate Nutrition 0.000 description 1
229960004129 sorbitan tristearate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000010414 supernatant solution Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
238000011100 viral filtration Methods 0.000 description 1
239000012904 visual particle Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8128—Antithrombin III
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO20016174A 1999-06-23 2001-12-18 Fremgangsmate ved opprenskning av antitrombin-III NO324627B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9902388A SE9902388D0 (sv)	1999-06-23	1999-06-23	Method for purification of proteins
PCT/SE2000/001193 WO2000078792A1 (fr)	1999-06-23	2000-06-08	Procede servant a purifier des proteines

Publications (3)

Publication Number	Publication Date
NO20016174D0 NO20016174D0 (no)	2001-12-18
NO20016174L NO20016174L (no)	2002-02-21
NO324627B1 true NO324627B1 (no)	2007-11-26

Family

ID=20416211

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20016174A NO324627B1 (no)	1999-06-23	2001-12-18	Fremgangsmate ved opprenskning av antitrombin-III

Country Status (13)

Country	Link
EP (1)	EP1185551B1 (fr)
JP (1)	JP4521143B2 (fr)
AT (1)	ATE477267T1 (fr)
AU (1)	AU776861B2 (fr)
CA (1)	CA2376986C (fr)
DE (1)	DE60044812D1 (fr)
DK (1)	DK1185551T3 (fr)
ES (1)	ES2349678T3 (fr)
NO (1)	NO324627B1 (fr)
NZ (1)	NZ516235A (fr)
PT (1)	PT1185551E (fr)
SE (1)	SE9902388D0 (fr)
WO (1)	WO2000078792A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004092218A1 (fr) *	2003-04-17	2004-10-28	Mitsubishi Pharma Corporation	Procede d'elaboration d'antithrombine de recombinaison
EP1685852A1 (fr) *	2005-02-01	2006-08-02	Fondation pour la Recherche Diagnostique	Set des sacs jetable pour l'inactivation virale des fluides biologiques
US20060223988A1 (en) *	2005-04-05	2006-10-05	National Research Laboratories, Ltd.	High Resolution Methods and Precipitating Reagents for Isolating Proteins from Proteinaceous Material
CN103059129B (zh) *	2013-01-28	2015-02-11	贵州泰邦生物制品有限公司	制造人抗凝血酶-iii制品的方法
WO2019086463A1 (fr)	2017-10-30	2019-05-09	Baxalta GmbH	Détergents compatibles avec l'environnement pour l'inactivation de virus enveloppés de lipides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS597693B2 (ja) *	1978-01-07	1984-02-20	株式会社ミドリ十字	抗トロンビン製剤及びその製法
US4977246A (en) *	1989-06-06	1990-12-11	Rorer Pharmaceutical Corporation	High recovery process for antihemophilic factor
SE9301582D0 (sv) *	1993-05-07	1993-05-07	Kabi Pharmacia Ab	Purification of plasma proteins
JPH08109140A (ja) *	1994-10-12	1996-04-30	Green Cross Corp:The	高血圧症予防治療剤

1999
- 1999-06-23 SE SE9902388A patent/SE9902388D0/xx unknown
2000
- 2000-06-08 ES ES00944505T patent/ES2349678T3/es not_active Expired - Lifetime
- 2000-06-08 WO PCT/SE2000/001193 patent/WO2000078792A1/fr not_active Ceased
- 2000-06-08 JP JP2001505550A patent/JP4521143B2/ja not_active Expired - Fee Related
- 2000-06-08 AU AU58594/00A patent/AU776861B2/en not_active Ceased
- 2000-06-08 DK DK00944505.7T patent/DK1185551T3/da active
- 2000-06-08 DE DE60044812T patent/DE60044812D1/de not_active Expired - Lifetime
- 2000-06-08 CA CA2376986A patent/CA2376986C/fr not_active Expired - Fee Related
- 2000-06-08 NZ NZ516235A patent/NZ516235A/xx not_active IP Right Cessation
- 2000-06-08 EP EP00944505A patent/EP1185551B1/fr not_active Expired - Lifetime
- 2000-06-08 PT PT00944505T patent/PT1185551E/pt unknown
- 2000-06-08 AT AT00944505T patent/ATE477267T1/de active
2001
- 2001-12-18 NO NO20016174A patent/NO324627B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
WO2000078792A1 (fr)	2000-12-28
SE9902388D0 (sv)	1999-06-23
NO20016174D0 (no)	2001-12-18
CA2376986C (fr)	2010-03-16
JP4521143B2 (ja)	2010-08-11
ES2349678T3 (es)	2011-01-10
AU776861B2 (en)	2004-09-23
CA2376986A1 (fr)	2000-12-28
EP1185551A1 (fr)	2002-03-13
AU5859400A (en)	2001-01-09
ATE477267T1 (de)	2010-08-15
NO20016174L (no)	2002-02-21
DK1185551T3 (da)	2010-11-22
PT1185551E (pt)	2010-11-12
JP2003502438A (ja)	2003-01-21
EP1185551B1 (fr)	2010-08-11
DE60044812D1 (de)	2010-09-23
NZ516235A (en)	2004-01-30

Legal Events

Date	Code	Title	Description
2015-01-26	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
JP5245079B2 (ja)	2013-07-24	タンパク質の収量増加方法
CA1339440C (fr)	1997-09-02	Methode pour stabiliser des solutions d'albumine humaine; solutions ainsi obtenues
JP2008120822A6 (ja)	2008-08-07	タンパク質溶液からアポリポタンパク質を除去する方法
CA1126652A (fr)	1982-06-29	Preparation d'antithrombine et procede de production
JP3133338B2 (ja)	2001-02-05	ウイルス的に安全な生物学的組成物の調製方法
AU549584B2 (en)	1986-01-30	Heat stabilization of plasma proteins
US7727743B2 (en)	2010-06-01	Method for stabilizing a cryoprecipitate of plasmatic proteins for being subjected to a viral inactivation thermal treatment
JPH0676337B2 (ja)	1994-09-28	高純度抗血友病性因子濃縮物の製造法
NO328450B1 (no)	2010-02-22	Stabilt farmasøytisk preparat inneholdende faktor VIII
EP1654284B1 (fr)	2009-04-15	Procede de preparation d'une solution d'alpha-1 antitrypsine
CN114787185B (zh)	2023-08-08	一种凝血因子ⅷ中间品的冻存方法
CA2376986C (fr)	2010-03-16	Procede servant a purifier des proteines
US6518406B1 (en)	2003-02-11	Method for purification of proteins
JP3024073B2 (ja)	2000-03-21	タンパク質中のウイルスを不活性化する方法
RU2814332C1 (ru)	2024-02-28	Способ криоконсервации промежуточного продукта фактора viii свертывания крови
DK175644B1 (da)	2005-01-03	Fremgangsmåde til stabilisering af biologiske og farmaceutiske midler under inaktivering af virale og bakterielle kontaminanter
US20020146409A1 (en)	2002-10-10	Methods for stabilizing lyophilized blood proteins
Grangeorge et al.	0	Process for stabilizing human albumin solutions and the solution obtained